# Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

> **NCT06713798** · PHASE2 · WITHDRAWN · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris**

## Conditions studied

- Metastatic Cancer Lung
- Advanced Lung Cancer
- CBNPC Cancer

## Interventions

- **DRUG:** Atezolizumab 1200 mg IV
- **DRUG:** Tiragolumab 600 mg IV

## Key facts

- **NCT ID:** NCT06713798
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01-30
- **Primary completion:** 2025-09-15
- **Final completion:** 2025-09-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Roche stopped thr peoduction of one of the study product.
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06713798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06713798, "Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06713798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*